References

Relapsed/refractory chronic lymphocytic leukemia (CLL)

10.1007/s11899-023-00700-z · 2023 · External reference

High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies

10.1182/blood-2018-01-826008 · 2018 · External reference

The connect CLL registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites

10.1182/bloodadvances.2019001145 · 2020 · External reference

Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States

10.1002/cam4.2268 · 2019 · External reference

Real-world testing and treatment patterns in chronic lymphocytic leukemia: a SEER patterns of care analysis

10.1002/cncr.31738 · 2019 · External reference

Real-world treatment patterns, adherence and healthcare resource utilization for chronic lymphocytic leukemia/small lymphocytic leukemia among veterans in the United States

10.1182/blood-2021-148716 · 2021 · External reference

Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes

10.3324/haematol.2013.086066 · 2014 · External reference

Real-world evaluation of treatment discontinuation and healthcare resource utilization in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

10.1182/blood-2023-179948 · 2023 · External reference

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

10.1056/nejmoa1400376 · 2014 · External reference

Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia

10.1056/nejmoa1713976 · 2018 · External reference

Acalabrutinib versus investigator's choice in relapsed/refractory chronic lymphocytic leukemia: final ASCEND trial results

10.1097/hs9.0000000000000801 · 2022 · External reference

Real-world outcomes upon second-line treatment in patients with chronic lymphocytic leukaemia

10.1111/bjh.18715 · 2023 · External reference

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

10.3324/haematol.2017.182907 · 2018 · External reference

Comparisons of real-world time-to-event end points in oncology research

10.1200/cci.20.00125 · 2021 · External reference